These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6125546)

  • 21. [Combined treatment with oral tretinoin and a dithranol paste in psoriasis].
    Pozo Carballido JL
    Actas Dermosifiliogr; 1978; 69(7-8):215-22. PubMed ID: 362835
    [No Abstract]   [Full Text] [Related]  

  • 22. Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa.
    Lorente J; Sabater F; Rivas MP; Fuste J; Risco J; Gómez M
    J Laryngol Otol; 2014 Jul; 128(7):591-8. PubMed ID: 25000552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.
    Dong Z; Birrer MJ; Watts RG; Matrisian LM; Colburn NH
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):609-13. PubMed ID: 8290571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes.
    Reichert U; Jacques Y; Grangeret M; Schmidt R
    J Invest Dermatol; 1985 Feb; 84(2):130-4. PubMed ID: 2578530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical effect of anthralin on 12-O-tetradecanoylphorbol-13-acetate-induced mouse epidermal ornithine decarboxylase activity, proliferation, and tumor promotion.
    De Young LM; Helmes CT; Chao WR; Young JM; Miller V
    Cancer Res; 1981 Jan; 41(1):204-8. PubMed ID: 7448761
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of tumor-promoting agents on density and morphometric parameters of mouse epidermal Langerhans and Thy-1+ cells.
    Baxter CS; Andringa A; Chalfin K; Miller ML
    Carcinogenesis; 1991 Jun; 12(6):1017-21. PubMed ID: 1675159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calmodulin inhibition by anthralin? Investigations in vitro and in vivo.
    Wollina U; Klinger R; Wetzker R; Knopf B
    Dermatologica; 1989; 179(2):61-3. PubMed ID: 2529149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [On the effect of fluocinolone acetonide on the DNA synthesis in the epidermis].
    Kalkoff KW; Born W
    Klin Wochenschr; 1965 Dec; 43(24):1335-7. PubMed ID: 5334373
    [No Abstract]   [Full Text] [Related]  

  • 29. Modification of late epidermal differentiation in photoaged skin treated with topical retinoic acid cream.
    Tur E; Hohl D; Jetten A; Panizzon R; Frenk E
    Dermatology; 1995; 191(2):124-8. PubMed ID: 8520058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of chrysarobin skin tumor promotion.
    DiGiovanni J; Kruszewski FH; Chenicek KJ
    Carcinogenesis; 1988 Aug; 9(8):1445-50. PubMed ID: 3135955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of anthralin and its derivatives on epidermal cell kinetics.
    Fisher LB; Maibach HI
    J Invest Dermatol; 1975 May; 64(5):338-41. PubMed ID: 1141709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of treatment with dithranol, etretinate and a combination of dithranol and etretinate on epidermal metabolism and histology. Mouse tail assay.
    Lubach D; Kietzmann M
    Arzneimittelforschung; 1988 Aug; 38(8):1167-70. PubMed ID: 3196412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
    Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
    Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation of tumor promoter-stimulated ornithine decarboxylase activity and DNA synthesis in mouse epidermis in vivo and in vitro by fluocinolone acetonide, a tumor-promotion inhibitor.
    Lichti U; Slaga TJ; Ben T; Patterson E; Hennings H; Yuspa SH
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3908-12. PubMed ID: 269443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis.
    Pradhan M; Singh D; Murthy SN; Singh MR
    Steroids; 2015 Sep; 101():56-63. PubMed ID: 26049018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relevance of gap junctions to stage I tumor promotion in mouse epidermis.
    Kalimi GH; Sirsat SM
    Carcinogenesis; 1984 Dec; 5(12):1671-7. PubMed ID: 6499119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis.
    Clement M; Hehir M; Phillips H; du Vivier A
    Br J Dermatol; 1983 Sep; 109(3):327-35. PubMed ID: 6615719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site variation in anthralin inflammation on forearm skin.
    Lawrence CM; Howel D; Shuster S
    Br J Dermatol; 1986 May; 114(5):609-13. PubMed ID: 3718851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of the treatment of psoriasis with dithranol in comparison with a combination of dithranol and a corticosteroid].
    Gloor M; Graf R; Wirth H; Landau M
    Hautarzt; 1983 Oct; 34(10):500-3. PubMed ID: 6643055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.